Octagon Capital Advisors LP Lowers Stake in Kymera Therapeutics, Inc. $KYMR

Octagon Capital Advisors LP lessened its position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 20.6% during the first quarter, Holdings Channel reports. The institutional investor owned 425,000 shares of the company’s stock after selling 110,000 shares during the quarter. Kymera Therapeutics accounts for 3.9% of Octagon Capital Advisors LP’s holdings, making the stock its 8th largest holding. Octagon Capital Advisors LP’s holdings in Kymera Therapeutics were worth $35,398,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in KYMR. Smartleaf Asset Management LLC increased its holdings in Kymera Therapeutics by 382.0% in the 4th quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock worth $42,000 after acquiring an additional 424 shares during the last quarter. Larson Financial Group LLC lifted its holdings in Kymera Therapeutics by 81.5% during the third quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock valued at $44,000 after purchasing an additional 349 shares during the last quarter. Osaic Holdings Inc. lifted its holdings in Kymera Therapeutics by 18,050.0% during the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock valued at $48,000 after purchasing an additional 1,083 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new position in Kymera Therapeutics during the fourth quarter worth about $63,000. Finally, Raymond James Financial Inc. bought a new position in Kymera Therapeutics during the second quarter worth about $73,000.

Kymera Therapeutics Price Performance

KYMR opened at $110.57 on Monday. The company has a fifty day moving average price of $96.24 and a 200-day moving average price of $86.65. The firm has a market capitalization of $9.10 billion, a P/E ratio of -30.97 and a beta of 1.95. Kymera Therapeutics, Inc. has a one year low of $36.65 and a one year high of $130.05.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings data on Thursday, April 30th. The company reported ($0.71) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.18. The company had revenue of $34.37 million for the quarter, compared to the consensus estimate of $8.27 million. Kymera Therapeutics had a negative return on equity of 24.71% and a negative net margin of 611.94%.The firm’s revenue was up 55.5% compared to the same quarter last year. During the same quarter last year, the business posted ($0.82) earnings per share. On average, analysts expect that Kymera Therapeutics, Inc. will post -3.28 earnings per share for the current year.

Insiders Place Their Bets

In other Kymera Therapeutics news, Director Bvf Partners L. P/Il sold 1,578,800 shares of the company’s stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $106.50, for a total value of $168,142,200.00. Following the transaction, the director directly owned 240,123 shares in the company, valued at $25,573,099.50. This represents a 86.80% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Nello Mainolfi sold 80,000 shares of the firm’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $115.29, for a total value of $9,223,200.00. Following the completion of the sale, the chief executive officer directly owned 666,568 shares in the company, valued at approximately $76,848,624.72. The trade was a 10.72% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 3,637,813 shares of company stock valued at $390,253,404 in the last ninety days. Corporate insiders own 15.98% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently issued reports on KYMR shares. Brookline Capital Markets reissued a “buy” rating on shares of Kymera Therapeutics in a research report on Monday, June 8th. Canaccord Genuity Group raised their price objective on shares of Kymera Therapeutics from $106.00 to $129.00 and gave the stock a “buy” rating in a report on Friday, June 26th. Bank of America lifted their price objective on shares of Kymera Therapeutics from $110.00 to $125.00 and gave the company a “buy” rating in a research note on Tuesday, June 30th. Loop Capital set a $97.00 target price on shares of Kymera Therapeutics in a report on Monday, June 8th. Finally, Royal Bank Of Canada downgraded Kymera Therapeutics from an “outperform” rating to a “sector perform” rating and increased their target price for the stock from $106.00 to $115.00 in a research report on Monday, July 13th. Twenty investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $122.64.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.